Hemodynamic profile of terlipressin and octreotide in cirrhosis with portal hypertension

Phase 4, randomised, single-blind trial of terlipressin and octreotide in Cirrhosis and Portal Hypertension (PH) (3 arms), sponsored by Fundació Clínic per a la Recerca Biomèdica. Primary endpoints: Change in hepatic venous pressure gradient at 30 minutes, Change in hepatic venous pressure gradient at 1 hour and 1 more. Started Feb 2020; status: completed.